Google
CARM 株価分析 — Carisma Therapeutics Inc. (Healthcare >> Biotechnology)
CARM に関するよくある質問
CARMのROE（自己資本利益率）は？
Carisma Therapeutics Inc.のROEは-927.57%です。
CARMの配当利回りは？
Carisma Therapeutics Inc.の配当利回りは0.00%です。
CARMの品質スコア（Quality Score）は？
当社のAIはCARMの総合財務品質を100点中54点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
CARMは今が買い時ですか？
当社AIのタイミングスコアは100点中0点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
CARMはどのセクターに属しますか？
Carisma Therapeutics Inc.はHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
CARM AI Analysis Summary
Our AI summary for CARM: Carisma Therapeutics Inc. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -927.57%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.00
Price
0
(0%)
Day Change
|
|
|---|
CARM, ファンダメンタルスコアはnot quite good ( ファンダメンタル = 54) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROEの伸びが低い
平均ROEが低い
ROEが昨年度比で低い
Last-year ROA is lower than last-2-years ROA.
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 61 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | N/A |
| PBV / Sector |
-0.12 / 5.20
|
| Earning Per Share | 0.19 |
| PE / Sector |
N/A / 19.97
|
| PEG or PE/Growth / Sector |
N/A / 1.22
|
| Average 1M Daily Value |
117.324975000000
|
| Average 1W Daily Value |
19.738540000000
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
58% |
| 配当 |
|
37% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:36 |
| Symbol | CARM |
| Name | CARISMA THERAPEUTICS INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 41.85 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 0.10 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 3675 Market Street, Philadelphia, PA, United States, 19104
Phone: 267 491 6422
Website: https://www.carismatx.com
Sector: Healthcare >> Biotechnology
Description: Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
